Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Calcineurin inhibitors (CNI), a potent immunosuppressive drug used in kidney transplant
recipients to prevent graft rejection, may cause renal impairment. The aim of this study is
to assess whether a CNI-free regimen with enteric-coated mycophenolate sodium and everolimus
is as safe and well tolerated as a standard regimen consisting of enteric-coated
mycophenolate sodium and cyclosporine microemulsion without a compromise in therapeutic
efficacy while resulting in an improved renal function.